Meet suzetrigine, a non-opioid that promises to avoid addiction risk. But some experts say it can't replace opioids ...
If the attention generated by BioSpace’s coverage of this landmark approval is any indication, Americans are hungry for ...
The FDA has approved a new non-opioid prescription medication, Journavx for adults with moderate to severe acute pain.
H.C. Wainwright analyst Andrew Fein increased the price target for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) to $550 from the previous $535, while maintaining a Buy rating on the stock.
These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...
The US Food and Drug Administration (FDA) has approved a non-opioid drug for severe post-surgical pain, which could “redefine ...
Exploring Analgesics as a Key Painkiller Types & Their Role in Pain ReliefUnited States, New York, Feb. 04, 2025 (GLOBE ...
Vertex just won approval for a drug to treat one of the most common health problems -- pain. The biotech company is offering an option for patients and doctors who don’t want to go for ...
FDA Approves Non-Opioid Treatment for Moderate to Severe Acute Pain as Agency Continues to Take Steps to Support New ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results